EIM
ITCI

Essex Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Essex Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,717
Closed -$6.56M – 327
2025
Q1 		$6.56M Sell
49,717
-7,198
-13% -$897K 1.37% 10
2024
Q4 		$4.75M Sell
56,915
-1,470
-3% -$121K 0.85% 32
2024
Q3 		$4.27M Buy
58,385
+26,937
+86% +$2.02M 0.74% 44
2024
Q2 		$2.15M Buy
31,448
+30,215
+2,451% +$2.1M 0.4% 100
2024
Q1 		$85.3K Sell
1,233
-496
-29% -$34.1K 0.02% 232
2023
Q4 		$124K Sell
1,729
-380
-18% -$21.9K 0.02% 235
2023
Q3 		$110K Sell
2,109
-20
-0.9% -$1.17K 0.02% 292
2023
Q2 		$135K Hold
2,129
– – 0.02% 291
2023
Q1 		$115K Sell
2,129
-26
-1% -$1.26K 0.02% 302
2022
Q4 		$114K Buy
+2,155
New +$108K 0.02% 297
2018
Q4 		– Sell
-33,384
Closed -$724K – 538
2018
Q3 		$724K Buy
33,384
+1,384
+4% +$28.9K 0.09% 267
2018
Q2 		$565K Buy
32,000
+4,557
+17% +$92.5K 0.07% 283
2018
Q1 		$578K Buy
+27,443
New +$535K 0.08% 258
2016
Q4 		– Sell
-84,488
Closed -$1.29M – 379
2016
Q3 		$1.29M Buy
84,488
+67,964
+411% +$2.75M 0.21% 119
2016
Q2 		$641K Sell
16,524
-1,933
-10% -$69.5K 0.11% 205
2016
Q1 		$513K Buy
+18,457
New +$615K 0.09% 222

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Essex Investment Management's ITCI Position: Q2 2025 in Review

Essex Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 49,717 shares — an estimated $6.56M sold.

Essex Investment Management first reported a position in ITCI in Q1 2016 and held it in 16 quarters. The position peaked at $6.56M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Essex Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Essex Investment Management sold 49,717 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $6.56M.
  • Essex Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 16 quarters.
  • Essex Investment Management's Intra-Cellular Therapies Inc. position peaked at $6.56M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Essex Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.